Similar companies
Income Statement (USD)
| Q1 '25 | QoQ | |
|---|---|---|
| Revenue | 2.2M | 226.5% |
| Gross Profit | 2.2M | 4819.7% |
| Operating expense | 38M | 2.8% |
| Net Income | -34M | 4.7% |
| EBITDA | -36M | 5.6% |
Balance Sheet (USD)
| Q1 '25 | QoQ | |
|---|---|---|
| Total Assets | 333M | 10.3% |
| Total Liabilities | 123M | 5.9% |
| Total Equity | 210M | 12.8% |
| Shares Outstanding | 130M | 7.4% |
Cash Flow (USD)
| Q1 '25 | QoQ | |
|---|---|---|
| Cash from operations | -38M | 37.1% |
| Cash from financing | -530,000 | 101.1% |
EPS
Financial Highlights for Tscan Therapeutics in Q1 '25
Tscan Therapeutics reported a revenue of 2.2M, which is a 226.5% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 2.2M, marking a 4819.7% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Operating Expenses for this period were 38M, showing a 2.8% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -34M, showing a 4.7% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -36M, showing a -5.6% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for Tscan Therapeutics with growth in revenue, gross profit, and net income. Higher operating expenses might indicate increased investments or potential inefficiencies. A decline in EBITDA signals potential operational challenges or increased costs.
